Skip to content

Clarity Pharmaceuticals – Radiopharmaceutical Therapies and Imaging

Clarity is a clinical stage radiopharmaceutical company developing next-generation products to improve treatment outcomes for children and adults with cancer

Home
Company
Pipeline
Technology
News
Investor Centre
LinkedIn
YouTube

Home
Company
Pipeline
Technology
News
Investor Centre
LinkedIn
YouTube

Notice of General Meeting

Notice of General Meeting July 2021 (click to browse)
Virtual Meeting Online Guide (click to browse)

Author: Glenn

Post navigation

PreviousPrevious post:Clarity expands clinical sites for SARTATE™ neuroblastoma trial NextNext post:Clarity commences Cu-64 SAR-bisPSMA prostate cancer trial

Clarity receives US FDA Fast Track Designation for the treatment of metastatic castration-resistant prostate cancer patients with Cu-67 SAR-bisPSMA
February 18, 2025
Clarity expands pipeline in breast cancer with Cu-64/67 SAR-trastuzumab: Pre-clinical data published and trastuzumab supply agreement in place
February 10, 2025
Clarity to present COBRA and CLARIFY abstracts at two world-leading conferences
January 28, 2025
Clarity receives U.S. FDA Fast Track Designation for Cu-64 SAR-bisPSMA in biochemical recurrence of prostate cancer
January 23, 2025
Clarity expands its pipeline with a novel optimised FAP-targeted radiopharmaceutical
December 18, 2024
Last patient assessment completed for diagnostic SARTATE trial in NETs
November 28, 2024

4 Cornwallis Street,
National Innovation Centre,
Eveleigh 2015 NSW
+61 (0)2 9209 4037

Investor Center

Scientific Presentations

About SAR-Technology

Copper Isotopes

Intellectual Property

bd@claritypharmaceuticals.com

© Clarity Pharmaceuticals 2025 Australia

SUBSCRIBE TO CLARITY’S NEWSLETTER

Sign up to receive the most recent news and updates.